{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:05:53Z","timestamp":1772132753401,"version":"3.50.1"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Abby Grace Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Aislinn\u2019s Wish Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"RTW Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"RTW Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"RTW Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R44AI172670"],"award-info":[{"award-number":["R44AI172670"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R44NS135667"],"award-info":[{"award-number":["R44NS135667"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    The potency assay is critical to ensure the effectiveness and consistency of recombinant Adeno-associated Virus (AAV) gene therapy vectors, especially clinical-grade products. AAV serotype 9 (AAV9), known for its neurotropic properties and ability to cross the blood-brain barrier, has been a favored vector for targeting neurogenetic diseases. However, assessing AAV9 biopotency has been challenging due to the insusceptibility of the commonly used cell lines to AAV9. To address this, we utilized a cell-based potency assay using the liver-derived human hepatoma (HuH-7) cell line to evaluate infection by self-complementary (sc)-AAV9 vector expressing human N-sulfoglucosamine sulfohydrolase (hSGSH), currently undergoing evaluation as a potential treatment for Mucopolysaccharidosis (MPS) IIIA. The potency of various scAAV9-h\n                    <jats:italic>SGSH<\/jats:italic>\n                    vector batches was tested in HuH-7 cells which reproducibly expressed the transgene, resulting in measurable SGSH production. The SGSH expression and vector genome copies of various vector batches correlated linearly with the viral vector dose (R\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20090.71\u20130.95), indicating a generally strong correlation. The reproducibility of the assay was demonstrated by consistent vector copy numbers and SGSH activity in transduced cells across multiple independent runs. Statistical analysis of the results showed high reliability, with relative intra-assay consistency showing a coefficient of variation (CV) of less than 20%) and inter-assay reproducibility with a CV of less than 25%) affirming the precision of the test. Additionally, our data also demonstrate that long-term (&gt;2.5 years) storage at 2\u20134\u00b0C had no impact on the biopotency of rAAV9 vector confirming long-term stability of the vectors. Hence, we have effectively assessed the biopotency of rAAV9 vector\n                    <jats:italic>in vitro<\/jats:italic>\n                    utilizing HuH-7 cells. Overall, this\n                    <jats:italic>in vitro<\/jats:italic>\n                    assay provides a practical and reliable method to assess AAV9 potency, offering a valuable alternative to animal models and supporting the functional quality and consistency of AAV9 gene therapy vector products in general.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0341451","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:22:47Z","timestamp":1772130167000},"page":"e0341451","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the biopotency of the rAAV9 vector In Vitro"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-3970","authenticated-orcid":true,"given":"Pratikshya","family":"Adhikari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Vorobiov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tierra A.","family":"Bobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0518-3726","authenticated-orcid":true,"given":"Haiyan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"pone.0341451.ref001","article-title":"The mucopolysaccharidoses.","volume-title":"The Online Metabolic and Molecular Bases of Inherited Disease","author":"EF Neufeld","year":"2019"},{"issue":"2","key":"pone.0341451.ref002","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10545-008-0838-5","article-title":"Sanfilippo syndrome: a mini-review","volume":"31","author":"MJ Valstar","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"pone.0341451.ref003","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13023-021-01880-8","article-title":"Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities","volume":"16","author":"Y Puckett","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"pone.0341451.ref004","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1515\/jpem-2020-0742","article-title":"Global epidemiology of mucopolysaccharidosis type III (Sanfilippo syndrome): an updated systematic review and meta-analysis","volume":"34","author":"W Kong","year":"2021","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"pone.0341451.ref005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/diagnostics11020273","article-title":"Epidemiology of mucopolysaccharidoses update","volume":"11","author":"B \u00c7elik","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"pone.0341451.ref006","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/humu.1189","article-title":"Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications","volume":"18","author":"G Yogalingam","year":"2001","journal-title":"Hum Mutat"},{"issue":"8","key":"pone.0341451.ref007","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2012.140","article-title":"Gene therapy approaches for lysosomal storage disease: next-generation treatment","volume":"23","author":"BJ Byrne","year":"2012","journal-title":"Hum Gene Ther"},{"issue":"4","key":"pone.0341451.ref008","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"S Daya","year":"2008","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"pone.0341451.ref009","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"S Duque","year":"2009","journal-title":"Mol Ther"},{"issue":"1","key":"pone.0341451.ref010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"KD Foust","year":"2009","journal-title":"Nat Biotechnol"},{"key":"pone.0341451.ref011","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.omtm.2018.07.005","article-title":"Targeting root cause by systemic scAAV9-hIDS gene delivery: functional correction and reversal of severe MPS II in mice","volume":"10","author":"H Fu","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"pone.0341451.ref012","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery","volume":"19","author":"H Fu","year":"2011","journal-title":"Mol Ther"},{"key":"pone.0341451.ref013","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.omtm.2020.10.014","article-title":"Targeting the root cause of mucopolysaccharidosis IIIA with a New scAAV9 gene replacement vector","volume":"19","author":"TA Bobo","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"16","key":"pone.0341451.ref014","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"DM McCarty","year":"2001","journal-title":"Gene Ther"},{"key":"pone.0341451.ref015","author":"U.S. Food and Drug Administration CBER","year":"2011"},{"issue":"6","key":"pone.0341451.ref016","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"C Zincarelli","year":"2008","journal-title":"Mol Ther"},{"key":"pone.0341451.ref017","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1743-422X-10-74","article-title":"A survey of ex vivo\/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype","volume":"10","author":"BL Ellis","year":"2013","journal-title":"Virol J"},{"issue":"6","key":"pone.0341451.ref018","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1006\/mthe.2000.0219","article-title":"Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors","volume":"2","author":"H Chao","year":"2000","journal-title":"Mol Ther"},{"issue":"5","key":"pone.0341451.ref019","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/cells12050785","article-title":"Various AAV serotypes and their applications in gene therapy: an overview","volume":"12","author":"SS Issa","year":"2023","journal-title":"Cells"},{"issue":"2","key":"pone.0341451.ref020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/humc.2013.208","article-title":"Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates","volume":"25","author":"DA Murrey","year":"2014","journal-title":"Hum Gene Ther Clin Dev"},{"key":"pone.0341451.ref021","first-page":"250","article-title":"A Quantitative In Vitro Potency Assay for Adeno-Associated Virus Vectors Encoding for the UGT1A1 Transgene. Mol Ther Methods Clin Dev","volume":"18","author":"SJ Aronson","year":"2020"},{"issue":"2","key":"pone.0341451.ref022","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/mt.2015.187","article-title":"Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector","volume":"24","author":"JC Grieger","year":"2016","journal-title":"Mol Ther"},{"issue":"4","key":"pone.0341451.ref023","article-title":"Effects of siRNA on RET\/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations","volume":"9","author":"HM Ali","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"pone.0341451.ref024","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF01799255","article-title":"A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type A (MPS IIIA)","volume":"19","author":"EA Karpova","year":"1996","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"pone.0341451.ref025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/v17020239","article-title":"Adeno-associated virus vectors: principles, practices, and prospects in gene therapy","volume":"17","author":"L Zwi-Dantsis","year":"2025","journal-title":"Viruses"},{"issue":"2","key":"pone.0341451.ref026","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molmed.2020.09.010","article-title":"Journey to the center of the cell: tracing the path of AAV transduction","volume":"27","author":"BP Dhungel","year":"2021","journal-title":"Trends Mol Med"},{"issue":"1","key":"pone.0341451.ref027","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/gt.2011.211","article-title":"Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs","volume":"20","author":"BL Ellis","year":"2012","journal-title":"Gene Ther"},{"issue":"4","key":"pone.0341451.ref028","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ng0498-325","article-title":"Human gene targeting by viral vectors","volume":"18","author":"DW Russell","year":"1998","journal-title":"Nat Genet"},{"key":"pone.0341451.ref029","first-page":"60","article-title":"Variables influencing fluorimetric N-sulfoglucosamine sulfohydrolase (SGSH) activity measurement in brain homogenates","volume":"5","author":"LS Whyte","year":"2015","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"pone.0341451.ref030","first-page":"30","article-title":"Assay acceptance criteria for multiwell-plate-based biological potency assays draft for consultation","volume":"12","author":"CJ Robinson","year":"2014","journal-title":"Bioprocess Int"},{"issue":"2","key":"pone.0341451.ref031","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/hgtb.2015.040","article-title":"Stability and compatibility of recombinant adeno-associated virus under conditions commonly encountered in human gene therapy trials","volume":"26","author":"AM Gruntman","year":"2015","journal-title":"Hum Gene Ther Methods"},{"issue":"1","key":"pone.0341451.ref032","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/hgtb.2016.180","article-title":"Assaying the stability and inactivation of AAV serotype 1 vectors","volume":"28","author":"DB Howard","year":"2017","journal-title":"Hum Gene Ther Methods"},{"key":"pone.0341451.ref033","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","article-title":"Entering the modern era of gene therapy","volume":"70","author":"XM Anguela","year":"2019","journal-title":"Annu Rev Med"},{"issue":"1","key":"pone.0341451.ref034","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"J-H Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"pone.0341451.ref035","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders","volume":"22","author":"Q Ling","year":"2023","journal-title":"Nat Rev Drug Discov"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:22:54Z","timestamp":1772130174000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341451"}},"subtitle":[],"editor":[{"given":"Chen","family":"Ling","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0341451","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]}}}